Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab in Aggressive Thyroid Cancer
NCT03246958Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2017
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in differentiated thyroid cancer (DTC), Medullary Thyroid Cancer (MTC), anaplastic thyroid cancer (ATC), sponsored by Dana-Farber Cancer Institute. Started Oct 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
differentiated thyroid cancer (DTC)Medullary Thyroid Cancer (MTC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT03246958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246958.